Corxel Raises $287 Million to Advance Cardiometabolic Drug Pipeline
Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, has announced the successful completion of its Series D1…
Read More...
Read More...
